Ethicon Completes Acquisition of NeuWave Medical, Inc.

J&J’s Ethicon device business has completed its acquisition of NeuWave Medical, Inc., manufacturer and marketer of minimally invasive soft-tissue microwave ablation systems.

Background

NeuWave Medical claims its products are currently used by physicians in over half of the top cancer centers in the United States. NeuWave Medical’s Certus® 140 ablation system’s high-powered computer and intuitive touchscreen interface enables activation of single or simultaneous multiple probe procedures for patients with soft-tissue lesions. This allows physicians to effectively tailor ablations for lesions of varying shapes and sizes. NeuWave Medical’s probe family includes conventional probes and the only Precision™ PR probe to limit the ablation length, allowing precise and controlled ablations.

Ethicon says the acquisition is consistent with the Johnson & Johnson Medical Devices’ strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology.

Company comments

for Ethicon

“Currently, there are limited treatment options for soft-tissue, non-resectable lesions,” said Michael del Prado, Company Group Chairman of Ethicon. “Together with NeuWave Medical, Ethicon can bring minimally invasive treatment options to make a difference for patients around the world. This is especially important for patients who may not be medically eligible for traditional surgery. We can now offer physicians and patients more choice in treatment options for soft-tissue lesions.

for NeuWave 

“NeuWave Medical’s unique ablation technology was originally developed by physicians and microwave scientists from the University of Wisconsin to maximize energy delivery to tissue, minimize invasiveness and provide physician-friendly workflow,” said Dan Sullivan, the CEO and President of NeuWave Medical. “This acquisition now provides NeuWave Medical with the ability to accelerate our innovation pipeline and expand the global footprint of our unique technologies, while allowing Ethicon to reach new patients by expanding the availability of a novel intervention that goes beyond surgical options in wide use today.”

Source: PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *